CEL-SCI Corporation is a clinical-stage biotechnology company focused on immunotherapy development for cancer and infectious diseases. The company's primary asset is Multikine, its lead candidate, which has completed Phase III clinical trials for head and neck cancer treatment. The company also operates the Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation platform designed to stimulate immune responses against bacterial, viral, and parasitic infections, as well as autoimmune conditions, allergies, and transplant rejection. The LEAPS technology also supports cancer immunotherapy applications.
The company's pipeline includes several LEAP product candidates in preclinical development stages, specifically CEL-2000, CEL-4000, and CEL-5000, which target potential rheumatoid arthritis treatments. CEL-SCI has established a strategic partnership with Saudi Arabian Pharma Company for Multikine commercialization in head and neck cancer.
Incorporated in 1983 and headquartered in Vienna, Virginia, CEL-SCI operates as a research and development-focused entity with no disclosed commercial revenue streams. The company's operations are concentrated in the United States, with development activities aligned to its clinical trial programs and platform technology advancement.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-6.27 | — | -1129.4% | |
| 2024 | $-0.51 | — | — | |
| 2023 | — | — | — | |
| 2022 | $-0.87 | $-0.87 | +6.5% | |
| 2021 | $-0.93 | $-0.90 | — | |
| 2020 | — | — | — | |
| 2019 | $-0.71 | $-0.71 | +62.0% | |
| 2018 | $-1.87 | $-1.87 | +2.1% | |
| 2017 | $-1.91 | $-1.83 | -2022.2% | |
| 2016 | $-0.09 | $-0.09 | +10.0% | |
| 2015 | $-0.10 | $-0.10 | +23.1% | |
| 2014 | $-0.13 | $-0.11 | +18.8% | |
| 2013 | $-0.16 | $-0.05 | -1500.0% | |
| 2012 | $-0.01 | $-0.01 | +93.3% | |
| 2011 | $-0.15 | $-0.13 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-09-30 | 2025-12-29 | 0001654954-25-014303 | SEC ↗ |
| 2024-09-30 | 2025-01-13 | 0001654954-25-000288 | SEC ↗ |
| 2023-09-30 | 2023-12-21 | 0001654954-23-015877 | SEC ↗ |
| 2022-09-30 | 2022-12-27 | 0001654954-22-016959 | SEC ↗ |
| 2021-09-30 | 2021-12-21 | 0001654954-21-013417 | SEC ↗ |
| 2020-09-30 | 2020-12-29 | 0001654954-20-013975 | SEC ↗ |
| 2019-09-30 | 2019-12-16 | 0001654954-19-013971 | SEC ↗ |
| 2018-09-30 | 2018-12-19 | 0001654954-18-014104 | SEC ↗ |
| 2017-09-30 | 2017-12-29 | 0001654954-17-011928 | SEC ↗ |
| 2016-09-30 | 2016-12-14 | 0001654954-16-004867 | SEC ↗ |
| 2015-09-30 | 2015-12-11 | 0001354488-15-005519 | SEC ↗ |
| 2014-09-30 | 2014-12-23 | 0001354488-14-006305 | SEC ↗ |
| 2013-09-30 | 2013-12-27 | 0001354488-13-007041 | SEC ↗ |
| 2012-09-30 | 2012-12-14 | 0001354488-12-006445 | SEC ↗ |
| 2011-09-30 | 2011-12-23 | 0001354488-11-005189 | SEC ↗ |